Clinical Trials Browser

Phase 2 × OTHER × Neoadjuvant Immunotherapy × Clear all

NCT07205497 2026-05-15

QNACTH

Phase 2 Active not recruiting

Neoadjuvant Immunotherapy

NCT07231575 2025-11-18

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

Phase 2 Not yet recruiting

Neoadjuvant Immunotherapy